November 22, 2013
Research and Markets
) has announced the addition of the
"Companion Biomarkers in Drug Development"
report to their offering.
are diagnostic tests that are specifically linked to a therapeutic drug either during its development or in the clinic. This linkage can be an important component of the drug development process; alternatively, the companion biomarker can be useful in ameliorating the regulatory process for the drug, or acting as an aid to therapeutic use in the clinic. Market opportunities for companion biomarkers are focused in drug development targets, drug development efficacy and clinical end points in four main therapeutic areas: oncology, cardiovascular, neurology and autoimmune. Using companion biomarkers yields safer and more efficacious drug products, reduces clinical trial and development costs, improves post-marketing safety profiles and salvages therapies that otherwise would not be granted approval. This report focuses on the role of companion diagnostic tests in drug development. It provides an in-depth discussion and analysis of the application of companion biomarkers to drug development and targeted therapeutics, as well as their use in clinical trials and the regulatory forum. The examination emphasizes new and developing technology platforms meant to aid in development of drugs for therapeutic use, and sometimes to be available as companion tests for these drugs in the clinic. Detailed tables and charts with sales forecasts and marketshare data are also included.
- Abbott Laboratories - Affymetrix - Biomax Informatics - Compugen - Electric Genetics - Eli Lilly and Company - ePitope Informatics - Fujitsu - GlaxoSmithKline - Hologic Gen-Probe - IBM
- INCOGEN, Inc - Ipsen - Jerini AG - Johnson & Johnson - Koada Technology - Luminex - Merck & Co, Inc - Novartis - Oracle - Oxonica - PamGene BV - Qiagen - Randox Laboratories- - Roche - Silicon Genetics - Thomson Reuters - Ventana Medical Systems - Wyeth - Zeptosens